Harrow Inc

HROW

Company Profile

  • Business description

    Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

  • Contact

    1A Burton Hills Boulevard
    Suite 200
    NashvilleTN37215
    USA

    T: +1 615 733-4730

    E: [email protected]

    https://www.harrow.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    373

Stocks News & Analysis

stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.
stocks

Investors overlooking ASX share’s potential

International expansion is a distraction from valuable local business.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,735.4083.10-0.94%
CAC 407,901.8350.72-0.64%
DAX 4024,002.3251.750.22%
Dow JONES (US)49,526.17537.29-1.07%
FTSE 10010,218.7723.400.23%
HKSE25,675.18287.55-1.11%
NASDAQ26,225.14410.08-1.54%
Nikkei 22560,815.95593.34-0.97%
NZX 50 Index12,762.92202.09-1.56%
S&P 5007,408.5092.74-1.24%
S&P/ASX 2008,505.3072.60-0.85%
SSE Composite Index4,131.533.86-0.09%

Market Movers